GlassScriptPhysician profile
Seren Durer
NPI 1326691379
$890.29
in general payments reported to CMS, 2019-2025
16 companies · $150 in 2025
The $150 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $223 · 2023: $305 · 2024: $213 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $586 · Education: $81.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.78 |
| Education | $81.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $178.00 | 2022-2024 | |
| Seagen INC. | $138.95 | 2022-2023 | Tukysa, Adcetris |
| Abbvie INC. | $97.11 | 2024-2025 | Epkinly, Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $94.77 | 2024-2025 | Fruzaqla, Iclusig, Alunbrig |
| Astrazeneca Pharmaceuticals LP | $70.14 | 2023-2025 | Imfinzi, Tagrisso |
| Celgene Corporation | $54.35 | 2022-2024 | Reblozyl |
| Genmab U.S., INC. | $45.16 | 2023 | Epkinly |
| Incyte Corporation | $42.84 | 2022-2023 | Jakafi |
| Lilly USA, LLC | $26.60 | 2025 | Jaypirca, Verzenio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.39 | 2023 | Gilotrif |
| Daiichi Sankyo INC. | $22.35 | 2024 | Enhertu |
| Alexion Pharmaceuticals, INC. | $20.52 | 2022 | |
| Genzyme Corporation | $20.28 | 2022 | |
| Array Biopharma INC | $19.66 | 2022 | |
| Merck Sharp & Dohme LLC | $17.84 | 2023 | Keytruda |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $15.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seren Durer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.